RecruitingNot ApplicableNCT02969798

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Preservation of Beta Cell Function in Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)


Sponsor

The University of Texas Health Science Center at San Antonio

Enrollment

700 participants

Start Date

Jan 1, 2014

Study Type

INTERVENTIONAL

Conditions

Summary

HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating pre-diabetes — specifically two types called impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) — to better understand how the body handles blood sugar before full diabetes develops. Healthy volunteers without pre-diabetes are also needed as a comparison group. **You may be eligible if...** - You are between 18 and 65 years old (male or female) - You have pre-diabetes (either IFG or IGT) OR you are a healthy control with normal blood sugar levels - Your BMI is between 24 and 40 - Your weight has been stable (within 4 lbs) for the past 3 months - You have no major organ disease based on physical exam or lab tests **You may NOT be eligible if...** - You have fully developed Type 1 or Type 2 diabetes - You have significant heart, kidney, liver, or other organ problems - You take certain medications that affect blood sugar - You are pregnant or planning to become pregnant - Your weight has changed significantly in the past 3 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDapagliflozin

10mg/day

DRUGSaxagliptin

5mg/day

DRUGPioglitazone

the dose will increase from 15 mg/day to 30 mg/day at month two

DRUGMetformin

starting at 1000 mg/day and increased to 2000 mg/day at month 2.


Locations(1)

The University of Texas Health Science Center at San Antonio

San Antonio, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02969798


Related Trials